Literature DB >> 23609195

Downregulated expression of hepatoma-derived growth factor (HDGF) reduces gallbladder cancer cell proliferation and invasion.

Maolan Li1, Jun Shen, Xiangsong Wu, Bingtai Zhang, Rui Zhang, Hao Weng, Qian Ding, Zhujun Tan, Guofeng Gao, Jiasheng Mu, Jiahua Yang, Yijun Shu, Runfa Bao, Qichen Ding, Wenguang Wu, Yang Cao, Yingbin Liu.   

Abstract

Hepatoma-derived growth factor (HDGF), a heparin-binding growth factor, has a wide range of biological functions, including mitogenic activity and vascular development. Recent studies demonstrated that HDGF also acted as an oncogene with aberrantly increased activity in multiple human cancers; however, little is known about the biological function of HDGF in gallbladder cancer (GBC). In this study, we focused on the clinical significance and biological functions of HDGF in GBC and found that Nuclear HDGF protein overexpression was frequently detected in GBC tissues. Patients with nuclear HDGF-positive tumors had worse overall survival than patients with HDGF-negative tumors. Furthermore, treatment of GBC lines with HDGF-targeting siRNA oligonucleotides (HDGF-siRNA) significantly reduced the proliferation of GBC-SD and SGC-996 cell lines and diminished both anchorage-independent growth on soft agar and cell migration. These data indicate that HDGF acts as a putative oncogene in GBC and could be a novel diagnostic and therapeutic target for GBC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23609195     DOI: 10.1007/s12032-013-0587-7

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  20 in total

1.  p53 negatively regulates the hepatoma growth factor HDGF.

Authors:  Yasushi Sasaki; Hideaki Negishi; Masashi Idogawa; Ikuko Yokota; Ryota Koyama; Masanobu Kusano; Hiromu Suzuki; Masahiro Fujita; Reo Maruyama; Minoru Toyota; Tsuyoshi Saito; Takashi Tokino
Journal:  Cancer Res       Date:  2011-10-17       Impact factor: 12.701

2.  Hepatoma-derived growth factor regulates breast cancer cell invasion by modulating epithelial--mesenchymal transition.

Authors:  San-Cher Chen; Mei-Lang Kung; Tsung-Hui Hu; Hsuan-Yu Chen; Jian-Ching Wu; Hsiao-Mei Kuo; Han-En Tsai; Yu-Wei Lin; Zhi-Hong Wen; Jong-Kang Liu; Ming-Hsin Yeh; Ming-Hong Tai
Journal:  J Pathol       Date:  2012-05-23       Impact factor: 7.996

3.  Hepatoma-derived growth factor is a novel prognostic factor for patients with pancreatic cancer.

Authors:  Hirokazu Uyama; Yasuhiko Tomita; Hideji Nakamura; Shoji Nakamori; Binglin Zhang; Yoshihiko Hoshida; Hirayuki Enomoto; Yorihide Okuda; Masato Sakon; Katsuyuki Aozasa; Ichiro Kawase; Norio Hayashi; Morito Monden
Journal:  Clin Cancer Res       Date:  2006-10-15       Impact factor: 12.531

4.  Tumorigenesis and prognostic role of hepatoma-derived growth factor in human gliomas.

Authors:  Shu-Shong Hsu; Chih-Hao Chen; Guei-Sheung Liu; Ming-Hong Tai; Jyh-Seng Wang; Jain-Ching Wu; Mei-Lang Kung; Elsa C Chan; Li-Feng Liu
Journal:  J Neurooncol       Date:  2011-10-26       Impact factor: 4.130

Review 5.  Gallbladder cancer: past, present and an uncertain future.

Authors:  C Boutros; M Gary; K Baldwin; P Somasundar
Journal:  Surg Oncol       Date:  2012-09-29       Impact factor: 3.279

6.  Ethyl pyruvate administration suppresses growth and invasion of gallbladder cancer cells via downregulation of HMGB1-RAGE axis.

Authors:  M-L Li; X-F Wang; Z-J Tan; P Dong; J Gu; J-H Lu; X-S Wu; L Zhang; Q-C Ding; W-G Wu; L-H Rao; J-S Mu; J-H Yang; H Weng; Q Ding; W-J Zhang; L Chen; Y-B Liu
Journal:  Int J Immunopathol Pharmacol       Date:  2012 Oct-Dec       Impact factor: 3.219

7.  Hepatoma-derived growth factor involved in the carcinogenesis of gastric epithelial cells through promotion of cell proliferation by Erk1/2 activation.

Authors:  Jianshan Mao; Zefeng Xu; Yongming Fang; Haijun Wang; Jinghong Xu; Jinjia Ye; Shu Zheng; Yongliang Zhu
Journal:  Cancer Sci       Date:  2008-11       Impact factor: 6.716

8.  Antibodies targeting hepatoma-derived growth factor as a novel strategy in treating lung cancer.

Authors:  Hening Ren; Zuoming Chu; Li Mao
Journal:  Mol Cancer Ther       Date:  2009-05-12       Impact factor: 6.261

9.  Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas.

Authors:  Céline Pinheiro; Adhemar Longatto-Filho; Cristovam Scapulatempo; Luísa Ferreira; Sandra Martins; Luc Pellerin; Mesquita Rodrigues; Venancio A F Alves; Fernando Schmitt; Fátima Baltazar
Journal:  Virchows Arch       Date:  2008-01-10       Impact factor: 4.064

10.  Diverse cellular transformation capability of overexpressed genes in human hepatocellular carcinoma.

Authors:  Jhy-Shrian Huang; Chuan-Chuan Chao; Teh-Li Su; Shiou-Hwei Yeh; Ding-Shinn Chen; Chiung-Tong Chen; Pei-Jer Chen; Yuh-Shan Jou
Journal:  Biochem Biophys Res Commun       Date:  2004-03-19       Impact factor: 3.575

View more
  19 in total

1.  Upregulation of nucleus HDGF predicts poor prognostic outcome in patients with penile squamous cell carcinoma bypass VEGF-A and Ki-67.

Authors:  Dawei Li; Zhen Han; Jikai Liu; Xiang Zhang; Juchao Ren; Lei Yan; Hainan Liu; Zhonghua Xu
Journal:  Med Oncol       Date:  2013-09-03       Impact factor: 3.064

2.  HDGF and PRKCA upregulation is associated with a poor prognosis in patients with lung adenocarcinoma.

Authors:  Honghong Jiang; Qiaofen Fu; Xin Song; Chunlei Ge; Ruilei Li; Zhen Li; Baozhen Zeng; Chunyan Li; Ying Wang; Yuanbo Xue; Rongcheng Luo; Weiyi Fang
Journal:  Oncol Lett       Date:  2019-09-05       Impact factor: 2.967

3.  Oxymatrine induces apoptosis and inhibits invasion in Gallbladder carcinoma via PTEN/PI3K/AKT pathway.

Authors:  Liqiang Qian; Xiaqin Li; Penghui Ye; Gang Wang; Wei Dai; Yan Liu; Quangen Gao; Genhai Shen
Journal:  Cytotechnology       Date:  2017-11-23       Impact factor: 2.058

4.  Chloride intracellular channel 1 (CLIC1) is activated and functions as an oncogene in pancreatic cancer.

Authors:  Jianhua Lu; Qian Dong; Bingtai Zhang; Xuefeng Wang; Bin Ye; Fei Zhang; Xiaoling Song; Guofeng Gao; Jiasheng Mu; Zheng Wang; Fei Ma; Jun Gu
Journal:  Med Oncol       Date:  2015-04-26       Impact factor: 3.064

5.  Correlation of HMGB1 expression to progression and poor prognosis of adenocarcinoma and squamous cell/adenosquamous carcinoma of gallbladder.

Authors:  Zilu Shi; Qian Huang; Jian Chen; Pengcheng Yu; Xiaosong Wang; Hong Qiu; Yijie Chen; Yangyang Dong
Journal:  Am J Transl Res       Date:  2015-10-15       Impact factor: 4.060

6.  Prognostic significance of nemo-like kinase (NLK) expression in patients with gallbladder cancer.

Authors:  Maolan Li; Shenglai Zhang; Zhiqiang Wang; Bingtai Zhang; Xiangsong Wu; Hao Weng; Qian Ding; Zhujun Tan; Ning Zhang; Jiasheng Mu; Jiahua Yang; Yijun Shu; Runfa Bao; Qichen Ding; Wenguang Wu; Yang Cao; Yingbin Liu
Journal:  Tumour Biol       Date:  2013-07-16

7.  The expression of hepatoma-derived growth factor in primary central nervous system lymphoma and its correlation with angiogenesis, proliferation and clinical outcome.

Authors:  San-Zhong Li; Yong-Bo Zhao; Wei-Dong Cao; Yan Qu; Peng Luo; Hai-Ning Zhen; Xiao-Yan Chen; Zhi-Feng Yan; Zhou Fei
Journal:  Med Oncol       Date:  2013-06-15       Impact factor: 3.064

8.  Downregulated expression of metastasis associated in colon cancer 1 (MACC1) reduces gallbladder cancer cell proliferation and invasion.

Authors:  Yong Wang; Qiang Hong; Jianjun Wang; Yuejun Fang; Conggang Hu
Journal:  Tumour Biol       Date:  2014-01-15

9.  Heterogeneity research in muscle-invasive bladder cancer based on differential protein expression analysis.

Authors:  Peng Fei Liu; Yan Wei Cao; Hai Ping Jiang; Yong Hua Wang; Xue Cheng Yang; Xin Sheng Wang; Hai Tao Niu
Journal:  Med Oncol       Date:  2014-08-02       Impact factor: 3.064

10.  Zinc finger X-chromosomal protein (ZFX) is a significant prognostic indicator and promotes cellular malignant potential in gallbladder cancer.

Authors:  Hao Weng; Xu'an Wang; Maolan Li; Xiangsong Wu; Zheng Wang; Wenguang Wu; Zhou Zhang; Yijian Zhang; Shuai Zhao; Shibo Liu; Jiasheng Mu; Yang Cao; Yijun Shu; Runfa Bao; Jian Zhou; Jianhua Lu; Ping Dong; Jun Gu; Yingbin Liu
Journal:  Cancer Biol Ther       Date:  2015-07-31       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.